# VYNE Therapeutics Inc. (VYNE) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/VYNE
## Company Profile
- Ticker: VYNE
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunology
## Stock Data
- Close: 28.56 USD
- Market cap: 22546532.008 USD
- Last updated: 2026-07-27
## Business Overview
VYNE Therapeutics is a dermatology and immunology company focused on skin disease and inflammatory biology. Its story is built around developing specialized therapies for dermatologic conditions.
## Why The Stock Is Moving

Current closing-price context is not available for VYNE.

## Geographic Base

VYNE is headquartered in the United States and listed on NASDAQ. It sits in specialty dermatology biotechnology.

## Business Model

The company depends on clinical progress, formulation or mechanism differentiation, and capital efficiency. Investors typically watch data updates and the company's ability to sharpen its dermatology franchise.

## Landscape Position

VYNE occupies a focused dermatology niche within biotech. The stock is driven by whether its skin-disease programs can create durable differentiation.

## Future Catalysts

- VYNE’s catalysts are dermatology and immunology programs, plus any update that shows the company can still keep the story alive. The stock remains early-stage and data-dependent.

## Recent News
- 2026-07-23 20:26 EST — [VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience](https://biopharmsignal.com/news/VYNE/vyne-therapeutics-provides-update-regarding-cash-dividend-reverse-stock-split-an-5aa0e568) — Source: VYNE Therapeutics Inc.
- 2026-07-21 12:00 EST — [VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience](https://biopharmsignal.com/news/VYNE/vyne-therapeutics-announces-1-for-50-reverse-stock-split-and-provides-update-reg-ea42613d) — Source: VYNE Therapeutics Inc.
- 2026-07-10 12:00 EST — [VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience](https://biopharmsignal.com/news/VYNE/vyne-therapeutics-declares-special-cash-dividend-in-connection-with-the-proposed-971ae5b2) — Source: VYNE Therapeutics Inc.
- 2025-12-17 13:00 EST — [VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement](https://biopharmsignal.com/news/VYNE/vyne-therapeutics-and-yarrow-bioscience-announce-merger-agreement-cb196680) — Source: VYNE Therapeutics Inc.
- 2025-11-06 13:00 EST — [VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update](https://biopharmsignal.com/news/VYNE/vyne-therapeutics-reports-2025-third-quarter-financial-results-and-provides-busi-83d99919) — Source: VYNE Therapeutics Inc.